Beckley Science in the Media

Thumbnail image for Psychedelic Science Conference 2013

Psychedelic Science Conference 2013

April 26, 2013 Beckley in the Media

The Psychedelic Science conference, co-hosted by the Beckley Foundation, brought together researchers from around the world to discuss research, clinical trials, and medical discoveries involving psychedelic substances. Amanda Feilding presented the results of the Beckley Foundation research programme, including our recent investigations into psilocybin and MDMA.

Continue Reading →
http://www.beckleyfoundation.org/wp-content/uploads/2013/05/mdma-pills.png

MDMA may help treat depression and PTSD, Channel 4 study suggests

September 28, 2012 Beckley in the Media

Research hints at therapeutic uses for MDMA – but the taboo surrounding psychoactive drugs prevents similar studies by Amanda Feilding Click here for original Article in The Guardian I was amused by Conal Urquhart’s description in the Observer of the novelist Lionel Shriver being sucked into an MRI brain scanner “that resembles a giant washing machine”. I see […]

Continue Reading →

Channel 4 to screen volunteers taking the drug Ecstasy

July 20, 2012 Beckley Science in the Media

An experiment in which volunteers take the dance drug Ecstasy is to be screened on Channel 4 in a first for British television. This research forms part of the Beckley Foundation/Imperial College Psychedelic Research Programme: a collaboration between Amanda Fielding and Prof. David Nutt’s team at Imperial College. July 2012 Click here for original article […]

Continue Reading →

Press Release: The Beckley Foundation-Imperial College Psychedelic Research Programme

January 26, 2012 Beckley Science in the Media

Press Release 25th January 2012 The Beckley Foundation-Imperial College Psychedelic Research Programme Surprising findings of Research: Potential therapeutic applications of psychedelic drugs fMRI brain scans show that psilocybin, the active ingredient in magic mushrooms, lowers the activity of specific brain regions. The finding contradicts the popular belief that psychedelic drugs increase brain activity, and has […]

Continue Reading →

MDMA for treating post traumatic stress disorder: 80% success rate. Beckley Foundation’s work on psilocybin also praised

July 8, 2011 Beckley Science in the Media

An article posted by Craig K. Comstock on the Huffington Post talks of the huge success of Michael Mithoefer’s study into the medicinal purposes of MDMA, in particular reference to treating post traumatic stress disorder (PTSD). After MDMA-assisted psychotherapy, 80% no longer met the diagnostic criteria for PTSD, as compared to only 25% in the […]

Continue Reading →

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.

January 19, 2011 Beckley Science in the Media

Authors: Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, Winton-Brown T, Nosarti C, O’ Carroll CM, Seal M, Allen P, Mehta MA, Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, Crippa JA, Atakan Z, McGuire PK. Neuropsychopharmacology. 2010 Feb;35(3):764-74. Abstract Delta-9-tetrahydrocannabinol (Delta-9-THC) and Cannabidiol (CBD), the two main ingredients […]

Continue Reading →

Does intravenous {Delta}9-tetrahydrocannabinol increase dopamine release? A SPET study.

January 19, 2011 Beckley Science in the Media

Authors: Barkus E, Morrison PD, Vuletic D, Dickson J, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S, Murray RM. J Psychopharmacol. 2010 Sep 17. [Epub ahead of print] Abstract Intravenous (IV) Δ9-tetrahydrocannabinol (THC) induces transient psychotic symptoms in healthy subjects and in schizophrenic patients, but the psychotomimetic mechanism is unknown. One […]

Continue Reading →

Disruption of Frontal Theta Coherence by Δ(9)-Tetrahydrocannabinol is Associated with Positive Psychotic Symptoms.

January 19, 2011 Beckley Science in the Media

Authors: Morrison PD, Nottage J, Stone JM, Bhattacharyya S, Tunstall N, Brenneisen R, Holt D, Wilson D, Sumich A, McGuire P, Murray RM, Kapur S, Ffytche DH. The Biomedical Research Centre, Institute of Psychiatry, King’s College London, Denmark Hill, UK. Neuropsychopharmacology. 2010 Dec 8 Abstract The main ingredient in cannabis, Δ(9)-tetrahydrocannabinol (THC), can elicit acute […]

Continue Reading →

The administration of psilocybin to healthy hallucinogen-experienced volunteers in a mock-fMRI environment: a preliminary investigation of tolerability

January 19, 2011 Beckley Science in the Media

Authors: Carhart-Harris RL¹², Williams TM², Sessa B², Tyacke RJ¹², Rich AS², Feilding A³, Nutt DJ¹² ¹ Imperial College London, Dept of Neuropsychopharmacology ² University of Bristol, Psychopharmacology Unit ³ The Beckley Foundation ²Corresponding author: r.carhart-harris@imperial.ac.uk Abstract: This study sought to assess the tolerability of intravenously administered psilocybin in healthy, hallucinogen-experienced volunteers in a mock-magnetic resonance […]

Continue Reading →

Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study

January 19, 2011 Beckley Science in the Media

Celia J. A. Morgan, PhD, Gráinne Schafer, BSc, Tom P. Freeman, BSc and H. Valerie Curran, PhD Clinical Psychopharmacology Unit, University College London, London, UK Correspondence: Correspondence: H. Valerie Curran, Clinical Psychopharmacology Unit, Clinical Health Psychology, University College London, Gower St, London WC1E 6BT, UK. Email: v.curran@ucl.ac.uk Background The two main constituents of cannabis, cannabidiol […]

Continue Reading →